Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen to Develop Diagnostic Chips with Philadelphia Children s Hospital

NEW YORK, Oct. 31 - Children’s Hospital of Philadelphia has purchased Nanogen’s NanoChip technology to under a special collaborative research agreement to develop clinical diagnostic assays for childhood genetic diseases, Nanogen said Tuesday.

 

Under the terms of the deal, Children's Hospital will provide laboratory resources, collaborative expertise, and product revenue in exchange for non-exclusive access to Nanogen's electronic DNA microarrays.

 

Nanogen and Children's Hospital have also agreed to publish and present the validated study results.

 

“The agreement with Children's Hospital broadens our development efforts by applying the NanoChip technology to the most challenging areas of genetic testing, clearly differentiating our product from other systems," Nanogen CEO Howard Birndorf said in a statement.

 

This is the first collaboration announced under Nanogen's Development Site Program. Nanogen has also entered into collaborative chip development agreements with the US Army and the Defense Advanced Research Projects Agency and has sold its chips to the National Cancer Institute, the Mayo Clinic, and Aventis.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.